Free tool
FAERS Monitor: Antara (Micronized)
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021695 or its brand name (Antara (Micronized), Fenofibrate). Reports on generic versions are filed under their own applications.
Reports
35,836
Serious
24,506
68% of reports
Hospitalization
12,455
Death reported
2,824
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,202
- diarrhoea2,135
- nausea2,066
- drug ineffective1,826
- headache1,583
- dyspnoea1,561
- off label use1,420
- dizziness1,405
- pain1,399
- fall1,376
- asthenia1,331
- acute kidney injury1,288
- vomiting1,241
- arthralgia1,196
- pruritus1,170
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 264 |
| 2005 | 257 |
| 2006 | 404 |
| 2007 | 311 |
| 2008 | 482 |
| 2009 | 553 |
| 2010 | 670 |
| 2011 | 971 |
| 2012 | 1,096 |
| 2013 | 1,084 |
| 2014 | 1,374 |
| 2015 | 2,216 |
| 2016 | 2,581 |
| 2017 | 2,513 |
| 2018 | 2,797 |
| 2019 | 2,729 |
| 2020 | 2,502 |
| 2021 | 2,269 |
| 2022 | 2,233 |
| 2023 | 2,161 |
| 2024 | 2,068 |
| 2025 | 2,335 |
| 2026 | 1,966 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,018,323 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| acute kidney injurySignal | 1,288 | 5.0 | 4.7 | 4,080 |
| fallSignal | 1,376 | 2.4 | 2.3 | 1,173 |
| astheniaSignal | 1,331 | 2.1 | 2.0 | 758 |
| diarrhoea | 2,135 | 1.9 | 1.9 | 1,006 |
| pruritus | 1,170 | 1.8 | 1.7 | 413 |
| arthralgia | 1,196 | 1.7 | 1.6 | 342 |
| fatigue | 2,202 | 1.7 | 1.6 | 600 |
| dizziness | 1,405 | 1.7 | 1.6 | 371 |
| dyspnoea | 1,561 | 1.6 | 1.5 | 379 |
| vomiting | 1,241 | 1.6 | 1.5 | 247 |
| nausea | 2,066 | 1.5 | 1.5 | 397 |
| headache | 1,583 | 1.5 | 1.4 | 256 |
| pain | 1,399 | 1.3 | 1.3 | 122 |
| off label use | 1,420 | 1.0 | 0.9 | 4 |
| drug ineffective | 1,826 | 0.8 | 0.8 | 84 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.